Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

SCOPE Analytic Treatment Interruption Protocol

Analytic Treatment Interruption in HIV Infection

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.

Who May Be Eligible (Plain English)

Who May Qualify: - Willing and able to provide written willing to sign a consent form - Age \>= 18 - Documented HIV infection - Antiretroviral therapy for at least 12 months - Screening plasma HIV RNA levels below level of detection (\< 40-75 copies/mL), and all available determinations in past 12 months also below level of detection (blips allowed) - Screening CD4+ T-cell count \>350 cells/uL - If of childbearing potential, willing to use two methods of contraception - Willing to receive counseling regarding HIV transmission risk mitigation Who Should NOT Join This Trial: - Pregnant or plans to become pregnant during the course of the study - Active hepatitis B, defined as (1) positive sAg or (2) positive cAb with negative sAb and positive HBV DNA - Active hepatitis C, defined as positive Hep C Ab with positive HCV RNA - Use of a non-nucleoside reverse transcriptase inhibitor and unable to switch regimen - Significant cardiovascular or cerebrovascular disease - Recent or prior (within past 5 years) malignancy - Severe kidney disease (CrCl \< 50 mL/min via Cockroft-Gault method) - Severe hepatic impairment (Child-Pugh Class C) or unstable liver disease - Concurrent treatment with immunomodulatory drugs - Unable or unwilling to use barrier protection or pre-exposure prophylaxis (PrEP) to prevent HIV transmission with sexual partners not known to be HIV-infected Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Willing and able to provide written informed consent * Age \>= 18 * Documented HIV infection * Antiretroviral therapy for at least 12 months * Screening plasma HIV RNA levels below level of detection (\< 40-75 copies/mL), and all available determinations in past 12 months also below level of detection (blips allowed) * Screening CD4+ T-cell count \>350 cells/uL * If of childbearing potential, willing to use two methods of contraception * Willing to receive counseling regarding HIV transmission risk mitigation Exclusion Criteria: * Pregnant or plans to become pregnant during the course of the study * Active hepatitis B, defined as (1) positive sAg or (2) positive cAb with negative sAb and positive HBV DNA * Active hepatitis C, defined as positive Hep C Ab with positive HCV RNA * Use of a non-nucleoside reverse transcriptase inhibitor and unable to switch regimen * Significant cardiovascular or cerebrovascular disease * Recent or prior (within past 5 years) malignancy * Severe kidney disease (CrCl \< 50 mL/min via Cockroft-Gault method) * Severe hepatic impairment (Child-Pugh Class C) or unstable liver disease * Concurrent treatment with immunomodulatory drugs * Unable or unwilling to use barrier protection or pre-exposure prophylaxis (PrEP) to prevent HIV transmission with sexual partners not known to be HIV-infected

Treatments Being Tested

OTHER

Treatment Interruption Arm

Individuals with HIV on suppressive ART will interrupt their ART.

Locations (1)

University of California San Francisco
San Francisco, California, United States